United States: Galmed's 600 mg AramcholTM Achieved a Regulatory Approvable Endpoint Showing NASH Resolution Without Worsening of Fibrosis, in NASH Patients, in the Global Phase 2b ARREST 52-Week Study

Press/Media

Period12 Jun 2018

Media coverage

1

Media coverage

  • TitleUnited States: Galmed's 600 mg AramcholTM Achieved a Regulatory Approvable Endpoint Showing NASH Resolution Without Worsening of Fibrosis, in NASH Patients, in the Global Phase 2b ARREST 52-Week Study
    Media name/outletThai News Service
    Country/TerritoryThailand
    Date12/06/18
    PersonsScott Friedman